Clinical Trials Logo

Advanced Malignancies clinical trials

View clinical trials related to Advanced Malignancies.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT04949191 Terminated - Clinical trials for Advanced Malignancies

The Purpose of the Study is to Continue to Provide Pemigatinib to Patients With Advanced Malignancies.

Start date: July 8, 2021
Phase: Phase 2
Study type: Interventional

Safety and tolerability of pemigatinib.in monotherapy or combination in patients that have participated in a previous parent study to treat advanced malignancies.

NCT ID: NCT03407976 Terminated - Clinical trials for Urothelial Carcinoma

Apatinib With Pembrolizumab in Previously Treated Advanced Malignancies

APPEASE
Start date: June 19, 2018
Phase: Phase 1
Study type: Interventional

This is an open label nonrandomized Phase I/ IIA trial designed to assess the safety, tolerability, and efficacy of apatinib in combination with pembrolizumab. Phase I will assess the safety of combining increasing oral daily doses of apatinib with a fixed dose of IV pembrolizumab every three weeks and will determine the RP2D (Recommended Phase 2 Dose). Phase II will assess the efficacy of the RP2D of apatinib in combination with pembrolizumab and provide additional safety and tolerability data in three disease-specific cohorts

NCT ID: NCT03277352 Terminated - Metastatic Cancer Clinical Trials

INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies

Start date: November 21, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this study is to determine the safety, tolerability, and efficacy of INCAGN01876 when given in combination with immune therapies.

NCT ID: NCT02959437 Terminated - Solid Tumors Clinical Trials

Azacitidine Combined With Pembrolizumab and Epacadostat in Subjects With Advanced Solid Tumors (ECHO-206)

Start date: February 27, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This is an open-label, Phase 1/2 study in subjects with advanced or metastatic solid tumors. The study has three separate treatment groups where separate epigenetic agents are evaluated with an immunotherapy combination. Treatment Group A will evaluate the DNA methyltransferase inhibitor azacitidine in combination with the programmed death receptor-1 (PD-1) inhibitor pembrolizumab and the indoleamine 2,3-dioxygenase (IDO-1) inhibitor epacadostat; Treatment Group B will evaluate the bromodomain and extra-terminal (BET) inhibitor INCB057643 with pembrolizumab and epacadostat; and Treatment Group C will evaluate the lysine-specific demethylase 1A (LSD1) inhibitor INCB059872 with pembrolizumab and epacadostat. The study will be divided into 2 parts (Part 1 and 2). Part 1 is a dose-escalation assessment to evaluate the safety and tolerability of the combination therapies. Once the recommended doses have been determined, subjects with previously treated NSCLC, microsatellite-stable colorectal cancer (CRC), head and neck squamous cell carcinoma, urothelial carcinoma, and melanoma will be enrolled into expansion cohorts in Part 2.

NCT ID: NCT02608268 Terminated - Clinical trials for Advanced Malignancies

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

Start date: November 23, 2015
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this first-in-human study of MBG453 was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of MBG453 administered i.v. as a single agent or in combination with PDR001 or decitabine in adult patients with advanced solid tumors

NCT ID: NCT02265510 Terminated - Solid Tumors Clinical Trials

An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

Start date: September 10, 2014
Phase: Phase 1/Phase 2
Study type: Interventional

This was a study of INCB052793 given to patients with advanced malignancies that was to be conducted in three phases; Phase 1a (Monotherapy) and Phase 1b (Combination Therapy) and Phase 2 (Combination therapy of INCB052793 with azacitidine and itacitinib with azacitidine). Phase 1 had two parts; a dose escalation (Part 1) and an expansion (Part 2).

NCT ID: NCT00724425 Terminated - Clinical trials for Advanced Malignancies

A Phase 1 Dose Escalation Study of IPI-493

Start date: July 2008
Phase: Phase 1
Study type: Interventional

IPI-493 is a potent inhibitor of heat shock protein 90 (Hsp90) and is orally bioavailable via a novel formulation.

NCT ID: NCT00652158 Terminated - Clinical trials for Advanced Malignancies

A Phase 1 Trial of Extended MLN8054 Dosing in Patients With Advanced Malignancies

Start date: April 2006
Phase: Phase 1
Study type: Interventional

This is a phase 1 clinical trial designed to evaluate increasing durations of MLN8054 oral dosing in patients with advanced malignancies. MLN8054 will be given once daily for 4 to 7 consecutive days per week for 2 to 3 weeks. Following the 2- to 3-week treatment period there will be a 2 week recovery period.

NCT ID: NCT00468260 Terminated - Clinical trials for Advanced Malignancies

The Effects of Patupilone on the Pharmacokinetics and Pharmacodynamics of Warfarin in Patients With Advanced Malignancies

Start date: May 2007
Phase: Phase 1
Study type: Interventional

To evaluate the effects of patupilone on the pharmacokinetics of warfarin in patients with advanced malignancies.